Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pilot study of everolimus for prevention of chronic graft-versus-host disease after allogeneic stem cell transplantation
2010-023630-24Phase 2Completed
- Sponsor
- GMIHO mbH
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in graft-versus-host disease (GVHD) and respiratory complication, sponsored by GMIHO mbH. Primary endpoints: Early everolimus discontinuation rate and Tolerability of everolimus. Started Jan 2011; status: completed.
02
Drugs
everolimus
03
Conditions
graft-versus-host disease (GVHD)respiratory complication
Beyond the preview
Go deeper on 2010-023630-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023630-24.